BeiGene Announces National Reimbursement Inclusion of VIDAZA by the State Medical Insurance Administration in China

Pharmaceutical Investing

BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that China’s State Medical Insurance Administration (SMIA) has included VIDAZA (azacitidine for injection) on its national reimbursement drug list (NRDL). As quoted in the press release: VIDAZA is a nucleoside metabolic inhibitor and …

BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that China’s State Medical Insurance Administration (SMIA) has included VIDAZA (azacitidine for injection) on its national reimbursement drug list (NRDL).

As quoted in the press release:

VIDAZA is a nucleoside metabolic inhibitor and was approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts and chronic myelomonocyte leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation.

“VIDAZA became commercially available in China in February and is the only approved hypomethylating agent shown to prolong survival for patients with MDS. With this national reimbursement coverage, we expect more patients to have an opportunity to benefit from VIDAZA in China,” commented Dr. Xiaobin Wu, General Manager of China and President of BeiGene, Ltd. “BeiGene is committed to improving patient access to high-quality, innovative cancer treatments.”

Click here to read the full press release.

The Conversation (0)
×